The findings are based on 280,000 people aged 18-65 who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine, known as Covishield in India, from February 2021 through to 11 March 2021 in Denmark and Norway.
Using national health records, they identified rates of events, such as heart attacks, strokes, deep vein blood clots and bleeding events within 28 days of receiving a first vaccine dose and
The researchers found 59 blood clots in the veins compared with 30 expected, corresponding to 11 excess events per 100,000 vaccinations.
This included a higher than expected rate of blood clots in the veins of the brain, known as cerebral venous thrombosis (2.5 events per 100,000 vaccinations), the said.
A large study in Denmark and Norway has found slightly increased rates of vein blood clots, including in the brain, among adults who had received their first dose of the Oxford-AstraZeneca COVID-19 vaccine, compared with expected rates in the general population. However, the study published in The BMJ on Wednesday, stresses that the risk of such adverse events is considered low. The researchers from University of Southern Denmark, and Norwegian Institute of Public Health, set out to compare rates of blood clots and related conditions after vaccination with the Oxford-AstraZeneca vaccine with those in the general populations of the two countries.
URL copied Image Source : FILE PHOTO/AP
The study published in The BMJ on Wednesday, stresses that the risk of such adverse events is considered low.
A large study in Denmark and Norway has found slightly increased rates of vein blood clots, including in the brain, among adults who had received their first dose of the Oxford-AstraZeneca COVID-19 vaccine, compared with expected rates in the general population.
However, the study published in The BMJ on Wednesday, stresses that the risk of such adverse events is considered low.
The researchers from University of Southern Denmark, and Norwegian Institute of Public Health, set out to compare rates of blood clots and related conditions after vaccination with the Oxford-AstraZeneca vaccine with those in the general populations of the two countries.
The team found no increase in the rate of arterial clots
New Delhi:
A large study in Denmark and Norway has found slightly increased rates of vein blood clots, including in the brain, among adults who had received their first dose of the Oxford-AstraZeneca COVID-19 vaccine, compared with expected rates in the general population.
However, the study published in The BMJ on Wednesday, stresses that the risk of such adverse events is considered low.
The researchers from University of Southern Denmark, and Norwegian Institute of Public Health, set out to compare rates of blood clots and related conditions after vaccination with the Oxford-AstraZeneca vaccine with those in the general populations of the two countries.
KUNA : Zero deaths, 471 new Coronavirus cases in Norway - Health kuna.net.kw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kuna.net.kw Daily Mail and Mail on Sunday newspapers.